Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.42 |
| ▸ | XIAP | P98170 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.39 |
| ▸ | CMA1 | P23946 | 3/20 | 0.37 |
| ▸ | MLX | Q9UH92 | 1/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21581232 | 1.00 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297438 | 1.00 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297466 | 1.00 | ELANE (0.42) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297455 | 0.96 | ELANE (0.40) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL10297429 | 0.96 | ELANE (0.40) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL17029371 | 0.96 | ELANE (0.40) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL29463850 | 0.92 | REN (0.40) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL25637921 | 0.91 | ELANE (0.46) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL30134415 | 0.90 | ELANE (0.45) | ELANEXIAPRENCMA1MLX | |
| SCHEMBL25638189 | 0.90 | ELANE (0.45) | ELANEXIAPRENCMA1MLX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134796-B2 | Methods of prediction of wound healing | WOUNDCHEK LABORATORIES (US), INC. (US) | 2024-11-05 | — | — | US | claimed |
| EP-3353316-B1 | METHODS OF PREDICTION OF WOUND HEALING | WOUNDCHEK LABORATORIES INC (US) | 2024-01-10 | — | — | EP | claimed |
| US-20230127290-A1 | MUSCLE REGENERATION | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-04-27 | — | — | US | claimed |
| EP-4746881-A1 | NEW CRYSTALLINE FORMS OF A DIPEPTIDYL-PEPTIDASE I INHIBITOR AND ITS USE IN THERAPY | Boehringer Ingelheim International GmbH (DE) | 2026-05-27 | — | — | EP | disclosed |
| EP-4735111-A1 | SINGLE-DOMAIN ANTIBODY FOR INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY | Université de Liège (BE) | 2026-05-06 | — | — | EP | disclosed |
| US-20260060930-A1 | New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases | BOEHRINGER INGELHEIM INT (DE) | 2026-03-05 | — | — | US | disclosed |
| WO-2026046911-A1 | A DIPEPTIDYL-PEPTIDASE I INHIBITOR FOR ITS USE IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2026-03-05 | — | — | WO | disclosed |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | Ela Pharma Ltd (IL) | 2025-09-11 | — | — | US | disclosed |
| EP-4597115-A2 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | Takeda Pharmaceutical Company Limited (JP) | 2025-08-06 | — | — | EP | disclosed |
| EP-4574040-A2 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | Takeda Pharmaceutical Company Limited (JP) | 2025-06-25 | — | — | EP | disclosed |
| US-20250172567-A1 | PEPTIDE QUANTITATION ASSAY FOR DIFFERENTIATING FULL-LENGTH HIGH MOLECULAR WEIGHT KININOGEN (HMWK) AND CLEAVED HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-29 | — | — | US | disclosed |
| US-20230182139-A1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-15 | — | — | US | disclosed |
| US-11668718-B2 | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-06-06 | — | — | US | disclosed |
| EP-3334343-B1 | EVACUATED BLOOD COLLECTION TUBES CONTAINING PROTEASE INHIBITORS FOR THE ASSESSMENT OF CONTACT SYSTEM ACTIVATION | TAKEDA PHARMACEUTICALS CO (JP) | 2022-10-19 | — | — | EP | disclosed |
| US-11458477-B2 | Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| CN-110547288-B | Blood processing method and blood collection tube | 爱科来株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114981661-A | Method for diagnosing fibrinolytic insufficiency associated with neutrophil extracellular traps | 斯特拉斯堡大学医院 | 2022-08-30 | — | — | CN | disclosed |
| CN-114716390-A | Compositions and methods for treating and/or preventing necrosis of cells or tissue | ELA制药有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-4005569-A2 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | ELA Pharma Ltd (IL) | 2022-06-01 | — | — | EP | disclosed |
| CN-107690429-B | Composition for the treatment and/or prevention of necrosis of cells or tissue, specifically targeting cathepsin C and/or CELA1 and/or CELA3A and/or enzymes structurally related thereto | ELA制药有限公司 | 2022-02-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060930-A1 | New crystalline Forms, new pharmaceutical Composition and Dose Regimen of a Dipeptidyl peptidase I inhibitor for the Treatment of Patients with Bronchiectasis or other DPP-I mediated Diseases | CTSC, DPP3, SERPINB1 | ELANE 35/4885XIAP 394/4885REN 155/4885 |
| US-20250282740-A1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CELL OR TISSUE NECROSIS SPECIFICALLY TARGETING CATHEPSIN C AND/OR CELA1 AND/OR CELA3A AND/OR STRUCTURALLY RELATED ENZYMES THERETO | CELA1, CTSG, CTSE | ELANE 36/4885XIAP 144/4885REN 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.